---
title: "Varegacestat (AL102) in Desmoid tumors: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Economic burden and healthcare resource utilization. Topics: Direct and indirect costs: systematic literature review; Danish registry healthcare resource utilization and medication use, 2009 to 2018; Danish registry visits and hospital days within 3 years of diagnosis; United States academic center resource utilization, 2011 to 2023; 13 further topics. 17 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Direct and indirect costs: systematic literature review

> “No studies evaluating direct or indirect costs of patients with DT were identified in the literature.”
> “No monetary costs from loss of employment and hospital travel expenses were reported in these studies.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.2-2"></a>

### Danish registry healthcare resource utilization and medication use, 2009 to 2018

> “Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018. For each patient, ten persons from the general population were randomly matched on birth year, sex, and region of residence.”
> “A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical). The average number of inpatient and outpatient visits, days of hospitalization, and additional surgical procedures were higher among DT patients than the comparison cohort.”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

<a id="topic-2.2.1.8.2-3"></a>

### Danish registry visits and hospital days within 3 years of diagnosis

> “Healthcare resource utilization of patients with DT was substantially higher than that in the comparison cohort, both 1 and 3 years after the diagnosis. Within 3 years after the index date, patients with DT had, on average, 1 inpatient and 7.1 outpatient visits as well as 7.5 days in the hospital compared with an average of 0.8 inpatient and 0.1 outpatient visits and 0.8 days in the hospital in the comparison cohort. The median duration of hospitalization for DT-related surgery was 5 days (interquartile range, 3–7).”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.2-4"></a>

### United States academic center resource utilization, 2011 to 2023

> “A retrospective cohort study was conducted at the University of Utah Health network. Eligible patients were diagnosed with DTs between January 1, 2011, and July 31, 2023, were ≥18 years old at diagnosis, and had ≥2 DT-related encounters.”
> “Healthcare resource utilization was quantified using administrative claims.”
> “88.5% of patients had at least one outpatient visit related to DTs, with an average number of 2.4 visits per patient per year. In contrast, only a small proportion of patients had emergency visits related to DTs (n = 5, 3.4%). Approximately one fifths of patients (n = 30, 20.3%) required hospitalizations related to DTs with a median length of stay per year of 4.5 days (IQR: 3–8, range: 1–35).”
> “Although there was no increase in the proportion of patients who engaged outpatient services, the median number of outpatient visits almost tripled in the event of symptomatic disease (7.2 per patient per year) and doubled during active disease (4.7 per patient per year).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.8.2-5"></a>

### Healthcare use by physical symptom burden in the United Kingdom and the Netherlands

> “DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation.”
> “DTF patients in the intermediate symptom burden–high pain and high symptom burden clusters were more frequently receiving additional care, mostly from a physiotherapist or psychologist (Table S4).”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

<a id="topic-2.2.1.8.2-6"></a>

### Medications for symptom management in the Desmoid Tumor Research Foundation natural history study

| Medication class | Overall (N = 322), n (%) | Current desmoid tumor (n = 225), n (%) | No current desmoid tumor (n = 97), n (%) |
| --- | --- | --- | --- |
| NSAIDs | “151 (47)” | “103 (46)” | “48 (49)” |
| Antidepressants | “60 (19)” | “41 (18)” | “19 (20)” |
| Anticonvulsants | “36 (11)” | “26 (12)” | “10 (10)” |
| Muscle relaxants | “39 (12)” | “28 (12)” | “11 (11)” |
| Opioids | “61 (19)” | “45 (20)” | “16 (16)” |
| None | “104 (32)” | “69 (31)” | “35 (36)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.2-7"></a>

### Monitoring frequency in the Desmoid Tumor Research Foundation natural history study

> “As expected, a higher proportion of participants (77%, 181/235) with a current DT were monitored (regular clinic visits and radiologic assessment, including computed tomography and magnetic resonance imaging) at least every 6 months relative to those without (54%, 49/91).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.2-8"></a>

### Work loss attributed to pain: SOS Desmoid survey as summarized in a systematic review

> “Studies [4, 41] assessing the impact of DT on employment and job productivity have reported that patients experience a negative impact on their employment due to their disease and find it frustrating being unable to work (26% stopped working and 10% worked part- time; see Table 1).”
> “Pain-related work disturbances included 17 patients (26%) who stopped working altogether and 7 (10%) who worked only part time due to pain”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.2-9"></a>

### Employment and financial difficulty at a United Kingdom sarcoma unit

> “DF patients experienced changes to their employment due to their disease and found it frustrating being unable to work and wanting to feel ‘normal’. Some patients felt discriminated due to enforced sick leave, which was demoralising and led to loss of progression within their job role. In addition, financial difficulty resulting from loss of employment and hospital travel expenses was a significant concern for several patients.”

Source: [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)

<a id="topic-2.2.1.8.2-10"></a>

### Interruption of work after treatment: Dutch focus groups

> “Participants reported that DTF had influenced their working life, as they had to stop working temporarily after treatment. This period ranges from a couple of weeks to two years and in one case not being able to work at all.”

Source: [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)

<a id="topic-2.2.1.8.2-11"></a>

### Economic burden of surgery: literature review

> “Since economic data related to DT surgery is lacking, reviews of surgery costs in soft-tissue sarcomas and of general costs of amputations were conducted.”
> “Tumors in the extremities have the highest risk of recurrence (30%-90%).”
> “Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.”

Source: [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)

<a id="topic-2.2.1.8.2-12"></a>

### Cost of 10-year active surveillance in NHS Scotland

> “To estimate the direct costs associated with active surveillance (AS), we adopted a conservative costing approach based on current NHS tariffs, focusing on imaging and clinic visit expenses. The study assumes a 10-year follow-up period. The current cost per MRI was £130. Based on current NHS tariffs, each appointment costs approximately £233.”
> “At a cost of roughly £130 per MRI scan, this translates to a total imaging cost of £2340 per patient. Assuming an equal number of clinic visits throughout the follow-up period, with each consultant-led clinic appointment costing £233 as per current NHS Scotland figures, the total combined cost of imaging and appointments exceeds £6500 per patient.”

Source: [Saraf et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12191607/)

<a id="topic-2.2.1.8.2-13"></a>

### Cost per outcome of sorafenib at Medicare Part D rates

> “Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day).”
> “At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year.”

Source: [Johns et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35112974/)

<a id="topic-2.2.1.8.2-14"></a>

### German statutory health insurance target population and annual treatment cost of nirogacestat

> “Adults with progressing desmoid tumours who require systemic treatment”
> “Approx. 350 to 630 patients”
> “Nirogacestat”
> “260,760.82”
> “Costs after deduction of statutory rebates (LAUER-TAXE® as last revised: 1 February 2026)”

Source: [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf)

<a id="topic-2.2.1.8.2-15"></a>

### Basis of the German patient numbers and treatment cost calculation for nirogacestat

> “The G-BA takes into account the patient numbers stated in the pharmaceutical company's dossier, which are, however, subject to uncertainty overall. There were methodological limitations and uncertainty regarding the percentages of desmoid tumours, which also relate exclusively to inpatients, under ICD-10 code D48.1. Furthermore, patients who had been ill for more than 5 years were not considered.”
> “If no maximum treatment duration is specified in the product information, the treatment duration is assumed to be one year (365 days), even if the actual treatment duration is different from patient to patient and/or is shorter on average.”
> “Nirogacestat 150 mg”
> “56 FCT”
> “€ 21,213.56”
> “€ 20,003.57”
> “No additionally required SHI services are taken into account for the cost representation.”

Source: [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)

<a id="topic-2.2.1.8.2-16"></a>

### Nirogacestat list price in England

> “The anticipated list price is £15,189.04 per 56 pack of 150‑mg tablets (company submission).”
> “The company has a commercial arrangement. This makes nirogacestat available to the NHS with a discount. The size of the discount is commercial in confidence.”

Source: [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat)

<a id="topic-2.2.1.8.2-17"></a>

### Resource use assumptions and intra-abdominal care needs in the NICE appraisal of nirogacestat

> “The EAG also noted that the company did not apply any resource use for complete response, and underestimated specialist visits with the other health states. Informed by clinical opinion, the EAG preferred a higher number of specialist visits for all health states, and an increased number of GP visits for stable disease.”
> “The committee preferred to apply higher resource-use values from the EAG base case, because this better reflected clinical practice.”
> “The clinical expert also explained that people with desmoid tumours, particularly intra-abdominal tumours, may need stomas, ureteric stents and home intravenous nutrition.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
